Abbott (ABT) Wins FDA and EU Approval for an AI-Powered Tool That Guides Artery Stent Placement

Abbott Laboratories (NYSE:ABT) is one of the best medical technology stocks to buy right now. On April 28, Abbott Laboratories (NYSE:ABT) announced that the US Food and Drug Administration (FDA) and European regulators granted clearance and CE Mark approval, respectively, for its next-generation Ultreon 3.0 software. The software is an AI-powered coronary imaging platform designed to assist cardiologists in treating blocked heart arteries.

Abbott (ABT) Wins FDA and EU Approval for an AI-Powered Tool That Guides Artery Stent Placement

Courtesy of Abbott Labs

Abbott said that Ultreon 3.0 is the first optical coherence tomography (OCT) system in both the US and Europe that combines high-resolution images of coronary artery plaque with AI-automated analysis in a single, integrated workflow. OCT works by using infrared light to capture detailed cross-sectional images of the inside of an artery, and the system achieves a full pullback scan in just one second.

The challenge the platform seeks to address is to enable doctors to place stents properly to restore blood flow in a blocked artery. Ultreon 3.0 addresses this challenge by using AI to analyze OCT images in real time and giving the physician a faster, more precise decision-making tool during the procedure.

The platform also offers an advantage over intravascular ultrasound, or IVUS, said Abbott. IVUS is a competing imaging approach. It added that unlike IVUS, Ultreon 3.0 delivers higher-resolution images while requiring little to no contrast dye. This way, it reduces the risk of contrast-induced kidney complications in some patients.

Abbott Laboratories (NYSE:ABT) is a diversified medical technology and healthcare company. It develops diagnostics, medical devices, nutrition products, and branded generic pharmaceuticals.

While we acknowledge the risk and potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best Augmented Reality Penny Stocks to Buy and 10 Best Gene Therapy Stocks to Buy in 2026.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1